$PRGO

Perrigo (PRGO) gained 3.77% on a $10M lawsuit settlement. Gilead (GILD) rose 3.8% after an analyst raised its price target. Kroger (KR) increased 3.87% despite 3K job cuts. Bristol-Myers (BMY) climbed 4.61% on positive drug trial results.

Perrigo (PRGO) may be a takeover target, with CVC Capital potentially evaluating a purchase to merge it with Cooper Consumer Health, according to trader speculation.

Elf Beauty (ELF) shares rose after Canaccord's sales tracker showed 11.6% year-over-year dollar sales growth, with Naturium brand up 74.3%. Edgewell (EPC) saw 3.0% sales growth, driven by Edge and Cremo shave products. Perrigo (PRGO) reported 9.3% year-over-year growth in private label infant formula sales.

BlackRock, Inc. disclosed a substantial acquisition of shares in Perrigo Company PLC on September 11, 2026, as per the Irish Takeover Panel's SAR 6 rules. The disclosure was made on September 14, 2026. BlackRock is the party making the disclosure, with no other persons acting in concert mentioned. The acquisition may impact Perrigo's shareholder structure and market position.

Perrigo (PRGO) reported weak Q2 2026 earnings with a 3.1% sales decline and 21% drop in core earnings. The company's gross and operating margins also fell. Despite paying a $0.29 dividend, risks include weak performance, asset sales, and leadership uncertainty following the abrupt departure of its CEO. Investors are advised to wait for a new CEO's plan before considering the stock.

Perrigo (PRGO) reported weaker Q2 self-care and specialty-care demand in Europe and lower store-brand minoxidil and Mederma comparisons, while U.S. OTC volumes turned positive in late July. Infant formula revenue rose 23% YoY. Core adjusted gross margin fell 250 bps to 37%. Perrigo sold Dermacosmetics for $359M, using proceeds to reduce debt, and reiterated its 2026 outlook, including about -$0.60 EPS from under-absorption.

Perrigo (Q2 2026 earnings call) said core net sales fell 3.1% due to temporary seasonal softness and European retailer destocking, while it gained market share in U.S. store-brand OTC and key European brands. The company maintained full-year 2026 guidance, expects $80m-$100m savings by 2027, and noted a $359m Dermacosmetics divestiture and reviews of Infant Formula and Oral Care.

Biotech stocks rose as several companies reported updates. Attovia Therapeutics (ATTO) jumped over 28% after its Nasdaq debut at $17 and a close at $21.90. American Well (AMWL) gained about 25% after Q2 loss narrowed to $9.6M, though revenue fell to $52.0M. Perrigo (PRGO) swung to Q2 net income of $74.5M. UroGen (URGN) rose after Q2 revenue increased to $72.5M.

Investing.com reports Perrigo (PRGO) shares rose 24.4% to $13.41 after the company posted Q2 2026 results above analyst estimates. All-in adjusted diluted EPS was $0.50 versus $0.34 expected, and revenue was about $1.02B versus $1.01B. Perrigo cited cost savings and its Three-S strategy, reaffirmed 2026 EPS guidance, and said €305.6M from the Dermacosmetics sale will aid debt reduction.

Perrigo Co. plc (PRGO) reported Q2 profit despite lower sales. Net income was $74.5M versus a $8.4M loss a year earlier. EPS was $0.53 versus a loss of $0.06. Net sales fell to $1.02B from $1.06B. Perrigo reaffirmed FY2026 outlook, with adjusted EPS of $2.00 to $2.30. Shares rose about 11% premarket to $12.